[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-361306-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-361306-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cost-effectiveness-analysis-of-disitamab-vedotin-plus-toripalimab-versus-chemotherapy-as-treatment-for-her2-expressing-advanced-urothelial-cancer-in-china","Cost-effectiveness analysis of disitamab vedotin plus toripalimab versus chemotherapy as treatment for HER2-expressing advanced urothelial cancer in China","","This cost-effectiveness analysis evaluates disitamab vedotin combined with toripalimab compared with chemotherapy for patients with HER2-expressing advanced urothelial cancer from the perspective of the Chinese healthcare system. Using a partitioned survival model based on the RC48-C016 trial, lifetime health outcomes and costs were simulated with QALYs and the ICER. Deterministic and probabilistic sensitivity analyses assessed robustness. Results showed disitamab vedotin plus toripalimab was not cost-effective under current pricing and exceeded China’s willingness-to-pay threshold.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cost-effectiveness-analysis-of-disitamab-vedotin-plus-toripalimab-versus-chemotherapy-as-treatment-for-her2-expressing-advanced-urothelial-cancer-in-china/361306/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cost-effectiveness-analysis-of-disitamab-vedotin-plus-toripalimab-versus-chemotherapy-as-treatment-for-her2-expressing-advanced-urothelial-cancer-in-china/361306.png","ImageObject",300,407,{"name":42,"@type":43},"mieayamfan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-26","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What treatment strategies were compared in the analysis?","Question",{"text":63,"@type":64},"The study compared disitamab vedotin plus toripalimab versus chemotherapy for patients with HER2-expressing advanced urothelial cancer in China.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were costs and health outcomes evaluated?",{"text":68,"@type":64},"A partitioned survival model simulated lifetime outcomes using QALYs and calculated the incremental cost-effectiveness ratio (ICER) for the two treatment strategies.",{"name":70,"@type":61,"acceptedAnswer":71},"What conclusion did the base-case and threshold analysis reach?",{"text":72,"@type":64},"The base-case ICER exceeded China’s willingness-to-pay threshold, and probabilistic sensitivity analysis showed a relatively low probability of cost-effectiveness at the threshold.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},361306,1790679934,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962090893677,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Open access Original research  \nTo cite: Jia Y, Zhu L, Kang S, et al. Cost-effectiveness analysis of disitamab vedotin plus toripalimab versus chemotherapy as treatment for HER2-expressing advanced urothelial cancer in China. BMJ Open 2026;16:e117595 . doi:10 . 1136/ bmjopen-2026-117595  \n► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[bmjopen-2026-117595](bmjopen-2026-117595)) .  \nReceived 29 January 2026 Accepted 31 July 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1School of Pharmacy, Hebei Medical University, Shijiazhuang, China  \n2Medical Insurance Office, The Second Hospital of Hebei Medical University, Shijiazhuang, China  \nCorrespondence to  \nMrs Xiaohui Wang; [19000976@hebmu.edu.cn](19000976@hebmu.edu.cn) and Dr Shuo Kang; [shuok628@hebmu.edu.cn](shuok628@hebmu.edu.cn)  \nCost-effectiveness analysis of disitamab vedotin plus toripalimab versus chemotherapy as treatment for HER2-expressing advanced urothelial cancer in China  \nYize Jia  ,1 Lin Zhu,1 Shuo Kang,2 Xiaohui Wang  1  \nABSTRACT  \nObjective HER2-expressing advanced urothelial cancer is associated with poor prognosis and substantial treatment burden, and the economic value of emerging combination therapies remains uncertain. This study aimed to evaluate whether disitamab vedotin combined with toripalimab is more cost-effective than chemotherapy for patients with HER2-expressing advanced urothelial cancer from the perspective of the Chinese healthcare system.  \nDesign and setting Based on the RC48-C016 trial (NCT05302284), a partitioned survival model was developed to simulate lifetime health outcomes and economic costs. Data were obtained from the RC48-C016 trial and other publicly available published literature. Participants Patients with HER2-expressing advanced or metastatic urothelial carcinoma in China were included in this study. They were assigned to receive either disitamab vedotin plus toripalimab or chemotherapy based on the treatment arms defined in the RC48-C016 trial.  \nPrimary and secondary outcome measures Economic value was assessed using quality-adjusted life years (QALYs) and the incremental cost-effectiveness ratio (ICER) . Model robustness was evaluated through deterministic sensitivity analysis and probabilistic sensitivity analysis.  \nResults The base-case analysis showed that disitamab vedotin plus toripalimab resulted in an incremental cost of US$16 101.81 and an incremental QALY gain of 0 .28, corresponding to an ICER of US$56 889.17 per QALY gained. This value exceeded China’s willingness-to-pay threshold of US$38 224 per QALY. Probabilistic sensitivity analysis showed that, at this threshold, disitamab vedotin plus toripalimab had a 38 .5% probability of being costeffective. These findings suggest that disitamab vedotin plus toripalimab is unlikely to be cost-effective undercurrent pricing.  \nConclusion The cost-effectiveness analysis indicated that disitamab vedotin plus toripalimab is not a cost-effective treatment option for patients with HER2-expressing advanced urothelial cancer in China.  \nINTRODUCTION  \nBladder cancer is associated with substantial morbidity and mortality worldwide. In 2022,  \nSTRENGTHS AND LIMITATIONS OF THIS STUDY   \n⇒ A partitioned survival model was developed to evaluate the cost-effectiveness of disitamab vedotin combined with toripalimab for HER2-expressing advanced urothelial cancer from the perspective of the Chinese healthcare system.  \n⇒ In this study, only the costs related to grade ≥3 adverse events were taken into account, while expenses associated with adverse events of lower grades were excluded.  \n⇒ From the perspective of the Chinese healthcare system, this analysis incorporated direct medical costs, i","cbCaiqXm0qZmZsCH","https://ap.wps.com/l/cbCaiqXm0qZmZsCH","pdf",914736,"English","# Abstract\n## Objective\n## Methods\n## Outcomes and Results\n## Conclusions\n# Strengths and Limitations\n## Modeling approach\n## Cost and utility inputs","[{\"question\":\"What treatment strategies were compared in the analysis?\",\"answer\":\"The study compared disitamab vedotin plus toripalimab versus chemotherapy for patients with HER2-expressing advanced urothelial cancer in China.\"},{\"question\":\"How were costs and health outcomes evaluated?\",\"answer\":\"A partitioned survival model simulated lifetime outcomes using QALYs and calculated the incremental cost-effectiveness ratio (ICER) for the two treatment strategies.\"},{\"question\":\"What conclusion did the base-case and threshold analysis reach?\",\"answer\":\"The base-case ICER exceeded China’s willingness-to-pay threshold, and probabilistic sensitivity analysis showed a relatively low probability of cost-effectiveness at the threshold.\"}]","Cost-effectiveness analysis of disitamab vedotin plus toripalimab versus chemotherapy as treatment for HER2-expressing advanced urothelial cancer in China | PDF",1790143895,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/23c81029a2738b0e5edde6be2fc49c0f.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bc50d11a4d9250a0866fbe5955b20557.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1436fe297f10348609335c957c4e080d.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2b8a79e10477eee020d3cdd5a881916.webp",980,1306]